↓ Skip to main content

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression

Overview of attention for article published in Einstein (São Paulo), January 2026
Altmetric Badge

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression
Published in
Einstein (São Paulo), January 2026
DOI 10.31744/einstein_journal/2026rc1689
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Postgraduate 1 14%
Unknown 6 86%
Readers by discipline
Readers by discipline Count As %
Unknown 7 100%